Added benefit over time and endpoint assessments

This analysis shows how the extent of added benefit for patient groups has changed from year to year, and how individual endpoint assessments relate to the determined added benefit. Each patient group is one unit of analysis.

Data status: 2026-10-29

Filters

1,064Decisions

1,748Patient groups

619With added benefit

546With evidence rating

Extent of added benefit by year

Select an extent in the legend to hide or show it.

* 2026: data until 2026-10-29

The chart counts patient groups, not decisions: a decision with three patient groups counts three times.

Every decision counts in the year of its own decision date, reassessments and new therapeutic indications included. The chart shows what the G-BA decided each year, not the current status of each drug.

“Deemed proven” only appears from 2022. It marks reserve antibiotics, whose added benefit the law deems proven without the G-BA rating its extent: a change in the law, not in G-BA practice.

Data table

Patient groups per year and extent of added benefit
Year	Major	Considerable	Minor	Non-quantifiable	Deemed proven	Not proven	Lesser benefit	Total
2011	0	1	0	0	0	3	0	4
2012	0	3	5	1	0	8	0	17
2013	0	3	3	3	0	26	0	35
2014	0	6	8	2	0	28	0	44
2015	2	17	15	4	0	51	0	89
2016	0	22	9	6	0	91	1	129
2017	0	10	5	7	0	44	0	66
2018	0	9	13	14	0	65	2	103
2019	0	16	14	17	0	86	0	133
2020	0	14	21	17	0	58	0	110
2021	7	19	17	24	0	126	2	195
2022	4	19	14	19	13	113	0	182
2023	0	11	17	16	4	114	0	162
2024	2	11	7	26	4	94	2	146
2025	3	14	19	24	14	131	0	205
2026*	0	6	13	21	4	83	1	128

Mortality

Added benefit	Ø	n.a.	Missing	↓↓	↓	↔	↑	↑↑
Major	0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %
Considerable	0 0.0 %		0 0.0 %	0 0.0 %	0 0.0 %
Minor			0 0.0 %	0 0.0 %	0 0.0 %
Non-quantifiable			0 0.0 %	0 0.0 %	0 0.0 %
Deemed proven	0 0.0 %	0 0.0 %		0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %
Not proven			0 0.0 %	0 0.0 %	0 0.0 %
Lesser benefit	0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %		0 0.0 %	0 0.0 %

Morbidity

Added benefit	Ø	n.a.	Missing	↓↓	↓	↔	↑	↑↑
Major	0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %
Considerable			0 0.0 %
Minor			0 0.0 %
Non-quantifiable			0 0.0 %	0 0.0 %
Deemed proven	0 0.0 %	0 0.0 %		0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %
Not proven			0 0.0 %					0 0.0 %
Lesser benefit	0 0.0 %	0 0.0 %	0 0.0 %				0 0.0 %	0 0.0 %

Quality of life

Added benefit	Ø	n.a.	Missing	↓↓	↓	↔	↑	↑↑
Major			0 0.0 %	0 0.0 %	0 0.0 %
Considerable			0 0.0 %	0 0.0 %	0 0.0 %
Minor			0 0.0 %	0 0.0 %
Non-quantifiable			0 0.0 %	0 0.0 %
Deemed proven	0 0.0 %	0 0.0 %		0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %
Not proven			0 0.0 %	0 0.0 %				0 0.0 %
Lesser benefit		0 0.0 %	0 0.0 %				0 0.0 %	0 0.0 %

Adverse effects

Added benefit	Ø	n.a.	Missing	↓↓	↓	↔	↑	↑↑
Major	0 0.0 %		0 0.0 %		0 0.0 %
Considerable	0 0.0 %		0 0.0 %
Minor	0 0.0 %		0 0.0 %
Non-quantifiable			0 0.0 %
Deemed proven	0 0.0 %	0 0.0 %		0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %	0 0.0 %
Not proven			0 0.0 %					0 0.0 %
Lesser benefit	0 0.0 %	0 0.0 %	0 0.0 %				0 0.0 %	0 0.0 %

How to read the matrices

Each column represents an endpoint assessment. Within that column, the percentage shows the share of patient groups with the respective added benefit; the number above it is the absolute count. Darker cells indicate larger shares. Ø means no data are available, n.a. means not assessable, and “Missing” indicates an incomplete endpoint overview. An association does not prove a causal influence on the decision.